A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models [scRNA-seq: Rd10]
Single-cell RNA-seq · mouse · 3 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart.
- Organism
- Mus musculus (mouse)
- Samples
- 3 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy modelsNature communications · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE234797_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA983249 and SRA study SRP443150. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 3 more — browse all 3 samples with per-sample file links →
- GSE238217 A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. [RNA-seq: Rd10] 24 samples shares rd10, demonstrates, pre-clinical, combination, repurposing, retinopathy, treatment
- GSE263877 A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models [scRNA-seq: Rpe65-KO] 3 samples shares mutation-agnostic, demonstrates, pre-clinical, combination, repurposing, retinopathy, treatment
- GSE238218 A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. 40 samples shares demonstrates, pre-clinical, combination, repurposing, retinopathy, treatment
- GSE238216 A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. [RNA-seq: RPE65-KO] 13 samples shares demonstrates, pre-clinical, combination, repurposing, retinopathy, treatment
- GSE327434 Halofantrine protects photoreceptors in multiple models of retinal degeneration [rd10] 10 samples shares rd10
- GSE338894 An orally active, gut-enriched AhR agonist demonstrates therapeutic efficacy in colitis through regulation of inflammation, barrier homeostasis, and fibrosis 50 samples shares demonstrates
- GSE275713 A novel noninvasive murine model of neonatal hypoxic ischemic encephalopathy demonstrates developmental delay and motor deficits with activation of inflammatory pathways in monocytes 46 samples shares demonstrates
- GSE274183 A novel noninvasive murine model of neonatal hypoxic ischemic encephalopathy demonstrates developmental delay and motor deficits with activation of inflammatory pathways in monocytes [scRNA-seq] 24 samples shares demonstrates
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.